Skip to main content
Terug
Watch Compare

BICYCLE THERAPEUTICS PLC

Datakwaliteit: 100%
BCYC
NASDAQ Manufacturing Chemicals
€ 4,94
▼ € 0,03 (-0,60%)
Marktkapitalisatie: 343,66 M
Prijs
€ 4,93
Marktkapitalisatie
343,66 M
Dagbereik
52-Weeksbereik
Volume
Openen —
50D / 200D Gem.
50D / 200D Gem.

Quick Summary

Belangrijkste Punten

Revenue grew 57,83% annually over 5 years — strong growth
Negative free cash flow of -252,03 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 47,94%
Capital efficient — spends only 3,24% of revenue on capex

Groei

Revenue Growth (5Y)
57,83%
Boven sectorgemiddelde (1,92%)
Revenue (1Y)105,77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-34,02%
Boven sectorgemiddelde (-54,44%)
ROIC-26,93%
Net Margin-301,66%
Op. Margin-340,38%

Veiligheid

Debt / Equity
N/A
Current Ratio10,66
Interest Coverage-1199,34

Waardering

PE (TTM|NTM)
-1,57 | -2,60
Onder sectorgemiddelde (-1,49)
P/B Ratio0,56
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -1,6 -1,5
P/B 0,6 1,6
ROE % -34,0 -54,4
Net Margin % -301,7 -41,5
Rev Growth 5Y % 57,8 1,9
D/E 0,3

Koersdoel Analisten

9 analisten
Buy
Huidig
€ 4,94
+154.2%
Koersdoel
€ 12,56
€ 6,00
€ 8,00
€ 36,00
Vooruitzicht
Forward K/W -2,60
Forward WPA -€ 1,90
Omzet Sch. 28,17 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,90
-€ 2,78 – -€ 0,70
28,17 M 10
FY2026 -€ 2,07
-€ 2,98 – -€ 1,30
31,02 M 11

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,95 -€ 0,29 +69,6%
Q32025 -€ 1,07 -€ 0,85 +20,4%
Q22025 -€ 0,93 -€ 1,14 -22,0%
Q12025 -€ 0,81 -€ 0,88 -8,8%

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0,79% weight
CNCR CNCR
0,77% weight
MEDX logo MEDX Horizon Kinetics Medical ETF
0,62% weight
NARCX NARCX
0,06% weight
NAPIX NAPIX
0,06% weight
ISCWX ISCWX
0,06% weight
VVJFX VVJFX
0,06% weight
SNTCX SNTCX
0,05% weight
SNTFX SNTFX
0,05% weight
SNTDX SNTDX
0,05% weight

All Fundamental Metrics

Growth
Revenue Growth (1Y) 105,77% Revenue Growth (3Y) 64,04%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 57,83% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 72,59 M Net Income (TTM) -218,96 M
ROE -34,02% ROA -27,44%
Gross Margin N/A Operating Margin -340,38%
Net Margin -301,66% Free Cash Flow (TTM) -252,03 M
ROIC -26,93% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,66
Interest Coverage -1199,34 Asset Turnover 0,09
Working Capital 669,54 M Tangible Book Value 618,48 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,57 Forward P/E -2,60
P/B Ratio 0,56 P/S Ratio 4,73
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 12,20 Fwd Earnings Yield N/A
FCF Yield -73,34%
Market Cap 343,66 M Enterprise Value -304,67 M
Per Share
EPS (Diluted TTM) -3,16 Revenue / Share 1,04
FCF / Share -3,62 OCF / Share -3,58
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 3,24% FCF Conversion 115,10%
SBC-Adj. FCF -289,04 M Growth Momentum 47,94

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 72,59 M 35,28 M 26,98 M 14,46 M 11,70 M
Net Income -218,96 M -169,03 M -180,66 M -112,72 M -66,82 M
EPS (Diluted) -3,16 -2,90 -5,08 -3,80 -2,67
Gross Profit
Operating Income -247,07 M -209,87 M -189,95 M -116,65 M -65,62 M
EBITDA
R&D Expenses 240,28 M 172,97 M 156,50 M 81,61 M 44,88 M
SG&A Expenses
D&A 6,42 M 7,17 M 6,55 M 3,69 M 1,41 M
Interest Expense 206.000,0 1,73 M 3,26 M 3,34 M 2,98 M
Income Tax 152.000,0 -4,77 M 1,46 M -1,52 M -1,66 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 717,60 M 956,87 M 595,34 M 410,61 M 479,79 M
Total Liabilities 107,62 M 163,81 M 224,41 M 139,83 M 133,54 M
Shareholders' Equity 609,98 M 793,06 M 370,93 M 270,78 M 346,25 M
Total Debt 30,70 M 30,70 M 30,32 M 29,87 M
Cash & Equivalents 628,11 M 879,52 M 526,42 M 339,15 M 438,70 M
Current Assets 682,89 M 928,61 M 561,87 M 369,38 M 458,56 M
Current Liabilities 56,98 M 67,23 M 69,54 M 53,34 M 36,24 M